Search results
Showing 801 to 850 of 4091 results for patient
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.
This indicator covers the percentage of patients with heart failure diagnosed within the preceding 15 months with a record of an offer of referral for an exercise-based rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM48
fistula creation for haemodialysis access. This should report details of patient selection, particularly about vascular anatomy,...
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.
Electrocautery cutting balloon treatment for pelviureteric junction obstruction (HTG205)
Evidence-based recommendations on electrocautery cutting balloon treatment for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting a catheter with a balloon and wire into the urinary tract.
View recommendations for HTG205Show all sections
Sections for HTG205
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
Insertion of endobronchial valves for persistent air leaks (HTG306)
Evidence-based recommendations on insertion of endobronchial valves for treatment of persistent air leaks. This involves inserting valves into the airways to reduce or stop air leaks so the rest of the lung can function normally.
View recommendations for HTG306Show all sections
Sections for HTG306
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Evidence-based recommendations on electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease. This involves applying low-energy electrical impulses to the sphincter to strengthen the muscle so that less reflux happens.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Balloon dilatation of systemic to pulmonary arterial shunts in children (HTG48)
Evidence-based recommendations on balloon dilatation of systemic to pulmonary arterial shunts in children. This involves inflating a balloon inserted into the area so blood can flow through more easily.
View recommendations for HTG48Show all sections
Sections for HTG48
Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults.
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
angioplasty for chronic thromboembolic pulmonary hypertension. Details of patient selection, all complications, and subsequent...
Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.
View recommendations for HTG175Show all sections
Sections for HTG175
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
compliance with the standard principles of infection prevention and control that patients and carers experience in their own homes? Any...
Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)
Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.
View recommendations for HTG213Show all sections
Sections for HTG213
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on endometrial cryotherapy for menorrhagia (heavy periods). This involves using cold temperatures to freeze and destroy the lining of the womb.
View recommendations for HTG101Show all sections
Sections for HTG101
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Coil embolisation of unruptured intracranial aneurysms (HTG63)
Evidence-based recommendations on coil embolisation of unruptured intracranial aneurysms. This involves placing coils inside the aneurysm using a thin tube to make the blood clot so it is less likely to burst.
View recommendations for HTG63Show all sections
Sections for HTG63
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.
Pemetrexed for the treatment of non-small-cell lung cancer (TA124)
Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.
Partial replacement of the meniscus of the knee using a biodegradable scaffold (HTG289)
Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.
View recommendations for HTG289Show all sections
Sections for HTG289
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)
Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.
This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS165Show all sections
Sections for QS165
- Quality statements
- Quality statement 1: Assessment of looked-after children and young people
- Quality statement 2: Assessment of care leavers
- Quality statement 3: Assessment of children and young people in contact with youth offending services
- Quality statement 4: Information and advice for adults
- Update information
- About this quality standard
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
studies should report the effect of the procedure on local tumour control and patient survival. Any explanatory notes(if applicable)...
the need for repeat procedures and quality-of-life measures. Details of patient selection should also be reported. Any explanatory...
Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)
This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.